Clinical Trial Update: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial assessing REMD-477, a glucagon receptor antagonist, for effects on glucose and adipocyte metabolism in individuals with Type 2 diabetes, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Insulin Resistance
• Type 2 Diabetes Mellitus

Drugs mentioned

• REMD-477

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Type 2 Diabetes, Glucose Tolerance Impaired | EARLY_Phase 1 | Status: COMPLETED